Clinicopathological significance of nuclear factor-κB activation in hepatocellular carcinoma

Hepatology Research

Volumn 41, Issue 3, 2011, Pages 240-249

  Yokoo, Hideki ^a,d   Yasuda, Jun ^a,b   Nakanishi, Kazuaki ^a,d   Chuma, Makoto ^a,d   Kamiyama, Toshiya ^d   Todo, Satoru ^d   Hirohashi, Setsuo ^a   Sakamoto, Michiie ^a,c  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b Department of Cell Biology   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical significance; Hepatocellular carcinoma; Immunohistochemistry; Nuclear factor B; Phosphorylated Akt

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN ANTIBODY; PROTEIN KINASE B;

ADVANCED CANCER; ANTIBODY SPECIFICITY; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 79951790071     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00758.x     Document Type: Article

References (33)

1. Nagao T, Inoue S, Goto S etal. Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis. Ann Surg 1987; 205: 33-40.
2. Nagao T, Inoue S, Yoshimi F etal. Postoperative recurrence of hepatocellular carcinoma. Ann Surg 1990; 211: 28-33.
3. Hui AM, Takayama T, Sano K etal. Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. J Hepatol 2000; 33: 975-9.
4. Shimada M, Hasegawa H, Gion T etal. Risk factors of the recurrence of hepatocellular carcinoma originating from residual cancer cells after hepatectomy. Hepatogastroenterology 1999; 46: 2469-75.
5. Nakanishi K, Sakamoto M, Yasuda J etal. Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res 2002; 62: 2971-5.
6. Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 1999; 253: 210-29.
7. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-27.
8. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86-90.
9. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986; 47: 921-8.
10. Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 2001; 159: 387-97.
11. Zhang G, Ghosh S. Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 2001; 107: 13-9.
12. Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988; 242: 540-6.
13. Sun B, Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 2008; 27: 6228-44.
14. Pikarsky E, Porat RM, Stein I etal. NF-[kappa]B functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
15. Haybaeck J, Zeller N, Wolf MJ etal. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16: 295-308.
16. Maeda S, Kamata H, Luo J-L, Leffert H, Karin M. IKK[beta] couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-90.
17. He G, Yu GY, Temkin V etal. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010; 17: 286-97.
18. Tai DI, Tsai SL, Chang YH etal. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer 2000; 89: 2274-81.
19. Qiao L, Zhang H, Yu J etal. Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. Hum Gene Ther 2006; 17: 280-90.
20. O'Neil BH, Buzkova P, Farrah H etal. Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas. Oncology 2007; 72: 97-104.
21. Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005; 103: 307-12.
22. Genda T, Sakamoto M, Ichida T etal. Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology 1999; 30: 1027-36.
23. Hirohashi S, Shimosato Y, Kameya T etal. Production of alpha-fetoprotein and normal serum proteins by xenotransplanted human hepatomas in relation to their growth and morphology. Cancer Res 1979; 39: 1819-28.
24. Kanai T, Hirohashi S, Upton MP etal. Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. Cancer 1987; 60: 810-9.
25. LCSGJ LCSGoJ. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 2nd edn. Tokyo: Kanehara, 2003.
26. Peroukides S, Bravou V, Varakis J, Alexopoulos A, Kalofonos H, Papadaki H. ILK overexpression in human hepatocellular carcinoma and liver cirrhosis correlates with activation of Akt. Oncol Rep 2008; 20: 1337-44.
27. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24: 7455-64.
28. Machuca C, Mendoza-Milla C, Cordova E etal. Dexamethasone protection from TNF-alpha-induced cell death in MCF-7 cells requires NF-kappaB and is independent from AKT. BMC Cell Biol 2006; 7: 9.
29. Mendoza-Milla C, Machuca Rodriguez C, Cordova Alarcon E etal. NF-kappaB activation but not PI3K/Akt is required for dexamethasone dependent protection against TNF-alpha cytotoxicity in L929 cells. FEBS Lett 2005; 579: 3947-52.
30. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res 2002; 62: 6770-8.
31. Kato T Jr, Delhase M, Hoffmann A, Karin M. CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol Cell 2003; 12: 829-39.
32. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 2010; 52: 88-95.
33. Milhollen MA, Traore T, Adams-Duffy J etal. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010; 116: 1515-23.